Te Arai BioFarma secures Meningitec, Meningococcal Disease Conjugate Vaccine
Te Arai BioFarma announced today that they have entered an agreement for Meningitec, Meningococcal C conjugate vaccine, in New Zealand. Meningitec was previously licensed worldwide by Pfizer. In keeping with our mission to supply New Zealand with affordable vaccines, the Meningitec price has been reduced by nearly 45%.
The availability of this conjugate vaccine is of great importance to the Gravatt family who created Te Arai BioFarma following the death of their son Zachary Gravatt at the age of 22 years from meningococcal C disease.
The Meningitec pre-filled syringe vaccine protects against the most deadly and most common vaccine preventable meningococcal strain in New Zealand – Meningococcal C. Meningitec is used in immunisation schedules around the world and was successfully used in Northland during 2011 to control the Meningococcal C outbreak.